trial

Metformin for Treatment of Antipsychotic-induced Dyslipidemia

NCTId NCT01778244
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 162 (actual)
Sponsored by Central South University
Primary completion 2011-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
162 (actual)
Study type
Interventional
Allocation
Randomized
Model
Factorial
Masking
Quadruple
Start
2008-11
Primary completion
2011-12
Eligibility
ALL · 18 Years · 50 Years

Interventions & indications

Drugs
Metformin

Sponsors

Central South UniversityLead Sponsor

Investigators

1
Renrong Wu, ProfPrincipal Investigator

Sites

1 total
Changsha, China

Facts & assertions

4 sourced
Enrollment
162
Phase
PHASE4
Primary Completion Date
2011-12
Status
COMPLETED
relationships
The graph out of here
drug
Metformin
drug
lead_sponsor
Central South University
company
indication
Dyslipidemia
indication
Dyslipidemias
indication
Schizophrenia
indication
investigator
Renrong Wu, Prof
person